MiNK Therapeutics Inc. (INKT) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
149 FIFTH AVENUE NEW YORK, NY 10010 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)Annual | Quarterly
| 6/30/2024 Q2 | 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | 12/31/2022 Q4 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 5,817,080 | 3,367,229 | 6,398,854 | 10,622,186 | 14,892,050 | 19,635,725 | |||
| Cash and cash equivalents | 5,817,080 | 3,367,229 | 6,398,854 | 10,622,186 | 14,892,050 | 19,635,725 | |||
| Prepaid expense | 59,394 | 53,111 | 41,959 | 265,847 | 309,075 | 298,667 | |||
| Other current assets | 122,477 | 177,964 | 29,341 | 166,026 | 320,890 | 470,300 | |||
| Total current assets: | 5,998,951 | 3,598,304 | 6,470,154 | 11,054,059 | 15,522,015 | 20,404,692 | |||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 894,992 | 953,977 | 991,458 | 1,057,864 | 1,066,743 | 1,066,910 | |||
| Total noncurrent assets: | 894,992 | 953,977 | 991,458 | 1,057,864 | 1,066,743 | 1,066,910 | |||
| TOTAL ASSETS: | 6,893,943 | 4,552,281 | 7,461,612 | 12,111,923 | 16,588,758 | 21,471,602 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 8,769,706 | 8,949,334 | 8,127,647 | 9,135,329 | 8,755,278 | 10,061,555 | |||
| Accounts payable | 3,486,999 | 3,911,973 | 4,280,894 | 4,885,638 | 6,001,900 | 5,823,000 | |||
| Accrued liabilities | 5,282,707 | 5,037,361 | 3,846,753 | 4,249,691 | 2,753,378 | 4,238,555 | |||
| Other liabilities | 2,338,554 | 2,453,251 | 2,266,408 | 2,329,480 | 2,494,716 | 2,621,611 | |||
| Total current liabilities: | 11,108,260 | 11,402,585 | 10,394,055 | 11,464,809 | 11,249,994 | 12,683,166 | |||
| Noncurrent Liabilities | |||||||||
| Liabilities, other than long-term debt | 31,600 | 48,072 | 63,980 | 79,342 | 9,814,545 | 9,189,739 | |||
| Due to related parties | ✕ | ✕ | ✕ | ✕ | ✕ | 9,720,368 | 9,081,239 | ||
| Other liabilities | 31,600 | 48,072 | 63,980 | 79,342 | 94,177 | 108,500 | |||
| Total noncurrent liabilities: | 31,600 | 48,072 | 63,980 | 79,342 | 9,814,545 | 9,189,739 | |||
| Total liabilities: | 11,139,860 | 11,450,657 | 10,458,035 | 11,544,151 | 21,064,539 | 21,872,905 | |||
| Equity | |||||||||
| Equity, attributable to parent | (20,299,207) | (18,055,449) | (13,580,793) | (9,495,364) | (4,475,781) | (401,303) | |||
| Common stock | 347 | 346 | 345 | 345 | 343 | 339 | |||
| Additional paid in capital | 117,296,454 | 115,772,085 | 114,670,386 | 113,728,172 | 112,522,794 | 110,829,900 | |||
| Accumulated other comprehensive loss | (385,780) | (430,947) | (313,188) | (401,811) | (373,803) | (292,468) | |||
| Accumulated deficit | (137,210,228) | (133,396,933) | (127,938,336) | (122,822,070) | (116,625,115) | (110,939,074) | |||
| Total equity: | (20,299,207) | (18,055,449) | (13,580,793) | (9,495,364) | (4,475,781) | (401,303) | |||
| Other undisclosed liabilities and equity | 16,053,290 | 11,157,073 | 10,584,370 | 10,063,136 | |||||
| TOTAL LIABILITIES AND EQUITY: | 6,893,943 | 4,552,281 | 7,461,612 | 12,111,923 | 16,588,758 | 21,471,602 | |||
Income Statement (P&L) (USD)Annual | Quarterly
| 6/30/2024 Q2 | 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | 12/31/2022 Q4 | ||
|---|---|---|---|---|---|---|---|---|
| Operating expenses | (3,829,914) | (5,500,104) | (5,223,561) | (6,343,344) | (5,854,096) | (7,889,209) | ||
| Other undisclosed operating loss | ||||||||
| Operating loss: | (3,829,914) | (5,500,104) | (5,223,561) | (6,343,344) | (5,854,096) | (7,889,209) | ||
| Nonoperating income (expense) | (18) | 8 | (29,365) | |||||
| Other nonoperating income (expense) | (18) | 8 | ||||||
| Loss from continuing operations: | (3,829,914) | (5,500,122) | (5,223,553) | (6,343,344) | (5,854,096) | (7,918,574) | ||
| Other undisclosed net income | 16,619 | 41,525 | 168,055 | 148,835 | ||||
| Net loss: | (3,813,295) | (5,458,597) | (5,223,553) | (6,343,344) | (5,686,041) | (7,769,739) | ||
| Other undisclosed net income attributable to parent | 107,287 | 146,389 | ||||||
| Net loss available to common stockholders, diluted: | (3,813,295) | (5,458,597) | (5,116,266) | (6,196,955) | (5,686,041) | (7,769,739) | ||
Comprehensive Income (USD)Annual | Quarterly
| 6/30/2024 Q2 | 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | 12/31/2022 Q4 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (3,813,295) | (5,458,597) | (5,223,553) | (6,343,344) | (5,686,041) | (7,769,739) | ||
| Other comprehensive income (loss) | 45,167 | (88,623) | (28,008) | (81,335) | ||||
| Other undisclosed comprehensive income (loss) | (138,479) | 332,801 | ||||||
| Comprehensive loss: | (3,768,128) | (5,597,076) | (5,312,176) | (6,371,352) | (5,767,376) | (7,436,938) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | 20,720 | 284,533 | 146,389 | (546,993) | ||||
| Comprehensive loss, net of tax, attributable to parent: | (3,768,128) | (5,576,356) | (5,027,643) | (6,224,963) | (5,767,376) | (7,983,931) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.